nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—melanoma	0.373	1	CbGaD
Fesoterodine—CYP3A4—Temozolomide—melanoma	0.1	0.284	CbGbCtD
Fesoterodine—CYP2D6—Vemurafenib—melanoma	0.0862	0.245	CbGbCtD
Fesoterodine—ABCB1—Dactinomycin—melanoma	0.0608	0.173	CbGbCtD
Fesoterodine—CYP3A4—Vemurafenib—melanoma	0.0548	0.156	CbGbCtD
Fesoterodine—ABCB1—Docetaxel—melanoma	0.0314	0.0892	CbGbCtD
Fesoterodine—CYP3A4—Docetaxel—melanoma	0.0188	0.0534	CbGbCtD
Fesoterodine—Dry cough—Bleomycin—melanoma	0.014	0.0949	CcSEcCtD
Fesoterodine—Gamma-glutamyltransferase increased—Vemurafenib—melanoma	0.00434	0.0294	CcSEcCtD
Fesoterodine—Dry skin—Vemurafenib—melanoma	0.00238	0.0161	CcSEcCtD
Fesoterodine—Gamma-glutamyltransferase increased—Temozolomide—melanoma	0.00222	0.015	CcSEcCtD
Fesoterodine—Infestation—Vemurafenib—melanoma	0.002	0.0135	CcSEcCtD
Fesoterodine—Infestation NOS—Vemurafenib—melanoma	0.002	0.0135	CcSEcCtD
Fesoterodine—Hepatic enzyme increased—Temozolomide—melanoma	0.00193	0.0131	CcSEcCtD
Fesoterodine—Pharyngolaryngeal pain—Docetaxel—melanoma	0.0018	0.0122	CcSEcCtD
Fesoterodine—Laryngeal pain—Docetaxel—melanoma	0.00178	0.0121	CcSEcCtD
Fesoterodine—Oedema peripheral—Vemurafenib—melanoma	0.00177	0.012	CcSEcCtD
Fesoterodine—Dry eye—Temozolomide—melanoma	0.00169	0.0114	CcSEcCtD
Fesoterodine—Eye disorder—Vemurafenib—melanoma	0.00168	0.0114	CcSEcCtD
Fesoterodine—Cardiac disorder—Vemurafenib—melanoma	0.00166	0.0113	CcSEcCtD
Fesoterodine—Mediastinal disorder—Vemurafenib—melanoma	0.00162	0.011	CcSEcCtD
Fesoterodine—Dysgeusia—Vemurafenib—melanoma	0.00153	0.0104	CcSEcCtD
Fesoterodine—Back pain—Vemurafenib—melanoma	0.00151	0.0102	CcSEcCtD
Fesoterodine—Gastroenteritis—Temozolomide—melanoma	0.00149	0.0101	CcSEcCtD
Fesoterodine—Cough—Vemurafenib—melanoma	0.00136	0.00924	CcSEcCtD
Fesoterodine—Face oedema—Carmustine—melanoma	0.00132	0.00898	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00132	0.00895	CcSEcCtD
Fesoterodine—Face oedema—Temozolomide—melanoma	0.00128	0.00867	CcSEcCtD
Fesoterodine—Infection—Vemurafenib—melanoma	0.00127	0.00858	CcSEcCtD
Fesoterodine—Nervous system disorder—Vemurafenib—melanoma	0.00125	0.00847	CcSEcCtD
Fesoterodine—Skin disorder—Vemurafenib—melanoma	0.00124	0.00839	CcSEcCtD
Fesoterodine—Dry skin—Temozolomide—melanoma	0.00121	0.00824	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Temozolomide—melanoma	0.00117	0.00792	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Vemurafenib—melanoma	0.0011	0.00746	CcSEcCtD
Fesoterodine—Fatigue—Vemurafenib—melanoma	0.0011	0.00745	CcSEcCtD
Fesoterodine—Constipation—Vemurafenib—melanoma	0.00109	0.00739	CcSEcCtD
Fesoterodine—Dysuria—Temozolomide—melanoma	0.00107	0.00726	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Temozolomide—melanoma	0.00106	0.00722	CcSEcCtD
Fesoterodine—Urinary tract infection—Carmustine—melanoma	0.00103	0.00696	CcSEcCtD
Fesoterodine—Infestation NOS—Temozolomide—melanoma	0.00102	0.00692	CcSEcCtD
Fesoterodine—Infestation—Temozolomide—melanoma	0.00102	0.00692	CcSEcCtD
Fesoterodine—Urinary tract infection—Temozolomide—melanoma	0.000992	0.00673	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Temozolomide—melanoma	0.000965	0.00655	CcSEcCtD
Fesoterodine—Hypersensitivity—Vemurafenib—melanoma	0.000939	0.00637	CcSEcCtD
Fesoterodine—Oedema peripheral—Carmustine—melanoma	0.000934	0.00634	CcSEcCtD
Fesoterodine—Asthenia—Vemurafenib—melanoma	0.000914	0.0062	CcSEcCtD
Fesoterodine—Urinary tract disorder—Temozolomide—melanoma	0.000905	0.00614	CcSEcCtD
Fesoterodine—Oedema peripheral—Temozolomide—melanoma	0.000903	0.00612	CcSEcCtD
Fesoterodine—Pruritus—Vemurafenib—melanoma	0.000901	0.00611	CcSEcCtD
Fesoterodine—Urethral disorder—Temozolomide—melanoma	0.000898	0.00609	CcSEcCtD
Fesoterodine—Eye disorder—Carmustine—melanoma	0.000886	0.00601	CcSEcCtD
Fesoterodine—Diarrhoea—Vemurafenib—melanoma	0.000872	0.00591	CcSEcCtD
Fesoterodine—Eye disorder—Temozolomide—melanoma	0.000856	0.00581	CcSEcCtD
Fesoterodine—Cardiac disorder—Temozolomide—melanoma	0.00085	0.00577	CcSEcCtD
Fesoterodine—Dizziness—Vemurafenib—melanoma	0.000842	0.00571	CcSEcCtD
Fesoterodine—Mental disorder—Carmustine—melanoma	0.000831	0.00564	CcSEcCtD
Fesoterodine—Mediastinal disorder—Temozolomide—melanoma	0.000826	0.0056	CcSEcCtD
Fesoterodine—Cough—Bleomycin—melanoma	0.000825	0.0056	CcSEcCtD
Fesoterodine—Dry skin—Docetaxel—melanoma	0.000807	0.00548	CcSEcCtD
Fesoterodine—Chest pain—Bleomycin—melanoma	0.000805	0.00546	CcSEcCtD
Fesoterodine—Abdominal pain upper—Docetaxel—melanoma	0.000805	0.00546	CcSEcCtD
Fesoterodine—Rash—Vemurafenib—melanoma	0.000803	0.00545	CcSEcCtD
Fesoterodine—Mental disorder—Temozolomide—melanoma	0.000803	0.00545	CcSEcCtD
Fesoterodine—Dermatitis—Vemurafenib—melanoma	0.000802	0.00544	CcSEcCtD
Fesoterodine—Back pain—Carmustine—melanoma	0.000798	0.00542	CcSEcCtD
Fesoterodine—Headache—Vemurafenib—melanoma	0.000798	0.00541	CcSEcCtD
Fesoterodine—Dysgeusia—Temozolomide—melanoma	0.000781	0.0053	CcSEcCtD
Fesoterodine—Confusional state—Bleomycin—melanoma	0.000778	0.00528	CcSEcCtD
Fesoterodine—Vision blurred—Carmustine—melanoma	0.000778	0.00528	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000777	0.00527	CcSEcCtD
Fesoterodine—Back pain—Temozolomide—melanoma	0.000772	0.00523	CcSEcCtD
Fesoterodine—Infection—Bleomycin—melanoma	0.000767	0.0052	CcSEcCtD
Fesoterodine—Nausea—Vemurafenib—melanoma	0.000757	0.00513	CcSEcCtD
Fesoterodine—Vision blurred—Temozolomide—melanoma	0.000752	0.0051	CcSEcCtD
Fesoterodine—Angina pectoris—Docetaxel—melanoma	0.000742	0.00503	CcSEcCtD
Fesoterodine—Angioedema—Temozolomide—melanoma	0.000729	0.00494	CcSEcCtD
Fesoterodine—Vertigo—Temozolomide—melanoma	0.000717	0.00486	CcSEcCtD
Fesoterodine—Infection—Dactinomycin—melanoma	0.000715	0.00485	CcSEcCtD
Fesoterodine—Palpitations—Temozolomide—melanoma	0.000705	0.00478	CcSEcCtD
Fesoterodine—Chest pain—Carmustine—melanoma	0.000703	0.00477	CcSEcCtD
Fesoterodine—Cough—Temozolomide—melanoma	0.000696	0.00472	CcSEcCtD
Fesoterodine—Confusional state—Carmustine—melanoma	0.000679	0.00461	CcSEcCtD
Fesoterodine—Infestation NOS—Docetaxel—melanoma	0.000679	0.0046	CcSEcCtD
Fesoterodine—Infestation—Docetaxel—melanoma	0.000679	0.0046	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000674	0.00458	CcSEcCtD
Fesoterodine—Infection—Carmustine—melanoma	0.000669	0.00454	CcSEcCtD
Fesoterodine—Dry mouth—Temozolomide—melanoma	0.000664	0.00451	CcSEcCtD
Fesoterodine—Tachycardia—Carmustine—melanoma	0.000657	0.00446	CcSEcCtD
Fesoterodine—Confusional state—Temozolomide—melanoma	0.000656	0.00445	CcSEcCtD
Fesoterodine—Infection—Temozolomide—melanoma	0.000647	0.00439	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Docetaxel—melanoma	0.000642	0.00435	CcSEcCtD
Fesoterodine—Nervous system disorder—Temozolomide—melanoma	0.000638	0.00433	CcSEcCtD
Fesoterodine—Feeling abnormal—Bleomycin—melanoma	0.000636	0.00431	CcSEcCtD
Fesoterodine—Skin disorder—Temozolomide—melanoma	0.000632	0.00429	CcSEcCtD
Fesoterodine—Fatigue—Dactinomycin—melanoma	0.000621	0.00421	CcSEcCtD
Fesoterodine—Urticaria—Bleomycin—melanoma	0.000613	0.00416	CcSEcCtD
Fesoterodine—Insomnia—Carmustine—melanoma	0.000609	0.00413	CcSEcCtD
Fesoterodine—Urinary tract disorder—Docetaxel—melanoma	0.000602	0.00408	CcSEcCtD
Fesoterodine—Oedema peripheral—Docetaxel—melanoma	0.0006	0.00407	CcSEcCtD
Fesoterodine—Somnolence—Carmustine—melanoma	0.000599	0.00406	CcSEcCtD
Fesoterodine—Urethral disorder—Docetaxel—melanoma	0.000597	0.00405	CcSEcCtD
Fesoterodine—Feeling abnormal—Dactinomycin—melanoma	0.000593	0.00402	CcSEcCtD
Fesoterodine—Insomnia—Temozolomide—melanoma	0.000589	0.00399	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Dactinomycin—melanoma	0.000589	0.00399	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Carmustine—melanoma	0.000582	0.00395	CcSEcCtD
Fesoterodine—Somnolence—Temozolomide—melanoma	0.000579	0.00393	CcSEcCtD
Fesoterodine—Constipation—Carmustine—melanoma	0.000576	0.00391	CcSEcCtD
Fesoterodine—Dyspepsia—Temozolomide—melanoma	0.000573	0.00389	CcSEcCtD
Fesoterodine—Eye disorder—Docetaxel—melanoma	0.000569	0.00386	CcSEcCtD
Fesoterodine—Abdominal pain—Dactinomycin—melanoma	0.000569	0.00386	CcSEcCtD
Fesoterodine—Hypersensitivity—Bleomycin—melanoma	0.000569	0.00386	CcSEcCtD
Fesoterodine—Cardiac disorder—Docetaxel—melanoma	0.000566	0.00384	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Temozolomide—melanoma	0.000562	0.00381	CcSEcCtD
Fesoterodine—Fatigue—Temozolomide—melanoma	0.000561	0.00381	CcSEcCtD
Fesoterodine—Constipation—Temozolomide—melanoma	0.000557	0.00378	CcSEcCtD
Fesoterodine—Feeling abnormal—Carmustine—melanoma	0.000555	0.00377	CcSEcCtD
Fesoterodine—Asthenia—Bleomycin—melanoma	0.000554	0.00376	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Carmustine—melanoma	0.000551	0.00374	CcSEcCtD
Fesoterodine—Mediastinal disorder—Docetaxel—melanoma	0.000549	0.00373	CcSEcCtD
Fesoterodine—Pruritus—Bleomycin—melanoma	0.000546	0.0037	CcSEcCtD
Fesoterodine—Feeling abnormal—Temozolomide—melanoma	0.000536	0.00364	CcSEcCtD
Fesoterodine—Mental disorder—Docetaxel—melanoma	0.000534	0.00362	CcSEcCtD
Fesoterodine—Abdominal pain—Carmustine—melanoma	0.000533	0.00361	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Temozolomide—melanoma	0.000532	0.00361	CcSEcCtD
Fesoterodine—Hypersensitivity—Dactinomycin—melanoma	0.00053	0.0036	CcSEcCtD
Fesoterodine—Dysgeusia—Docetaxel—melanoma	0.000519	0.00352	CcSEcCtD
Fesoterodine—Urticaria—Temozolomide—melanoma	0.000517	0.00351	CcSEcCtD
Fesoterodine—Asthenia—Dactinomycin—melanoma	0.000516	0.0035	CcSEcCtD
Fesoterodine—Abdominal pain—Temozolomide—melanoma	0.000515	0.00349	CcSEcCtD
Fesoterodine—Back pain—Docetaxel—melanoma	0.000513	0.00348	CcSEcCtD
Fesoterodine—Hypersensitivity—Carmustine—melanoma	0.000496	0.00337	CcSEcCtD
Fesoterodine—Diarrhoea—Dactinomycin—melanoma	0.000492	0.00334	CcSEcCtD
Fesoterodine—Rash—Bleomycin—melanoma	0.000487	0.0033	CcSEcCtD
Fesoterodine—Dermatitis—Bleomycin—melanoma	0.000486	0.0033	CcSEcCtD
Fesoterodine—Asthenia—Carmustine—melanoma	0.000483	0.00328	CcSEcCtD
Fesoterodine—Hypersensitivity—Temozolomide—melanoma	0.00048	0.00325	CcSEcCtD
Fesoterodine—Palpitations—Docetaxel—melanoma	0.000469	0.00318	CcSEcCtD
Fesoterodine—Asthenia—Temozolomide—melanoma	0.000467	0.00317	CcSEcCtD
Fesoterodine—Cough—Docetaxel—melanoma	0.000463	0.00314	CcSEcCtD
Fesoterodine—Diarrhoea—Carmustine—melanoma	0.000461	0.00313	CcSEcCtD
Fesoterodine—Pruritus—Temozolomide—melanoma	0.000461	0.00312	CcSEcCtD
Fesoterodine—Nausea—Bleomycin—melanoma	0.000458	0.00311	CcSEcCtD
Fesoterodine—Rash—Dactinomycin—melanoma	0.000454	0.00308	CcSEcCtD
Fesoterodine—Chest pain—Docetaxel—melanoma	0.000452	0.00306	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000449	0.00304	CcSEcCtD
Fesoterodine—Dizziness—Carmustine—melanoma	0.000445	0.00302	CcSEcCtD
Fesoterodine—Diarrhoea—Temozolomide—melanoma	0.000445	0.00302	CcSEcCtD
Fesoterodine—Dry mouth—Docetaxel—melanoma	0.000442	0.003	CcSEcCtD
Fesoterodine—Confusional state—Docetaxel—melanoma	0.000437	0.00296	CcSEcCtD
Fesoterodine—Dizziness—Temozolomide—melanoma	0.00043	0.00292	CcSEcCtD
Fesoterodine—Infection—Docetaxel—melanoma	0.00043	0.00292	CcSEcCtD
Fesoterodine—Nausea—Dactinomycin—melanoma	0.000428	0.0029	CcSEcCtD
Fesoterodine—Rash—Carmustine—melanoma	0.000425	0.00288	CcSEcCtD
Fesoterodine—Nervous system disorder—Docetaxel—melanoma	0.000425	0.00288	CcSEcCtD
Fesoterodine—Dermatitis—Carmustine—melanoma	0.000424	0.00288	CcSEcCtD
Fesoterodine—Tachycardia—Docetaxel—melanoma	0.000423	0.00287	CcSEcCtD
Fesoterodine—Headache—Carmustine—melanoma	0.000422	0.00286	CcSEcCtD
Fesoterodine—Skin disorder—Docetaxel—melanoma	0.000421	0.00285	CcSEcCtD
Fesoterodine—Rash—Temozolomide—melanoma	0.00041	0.00278	CcSEcCtD
Fesoterodine—Dermatitis—Temozolomide—melanoma	0.00041	0.00278	CcSEcCtD
Fesoterodine—Headache—Temozolomide—melanoma	0.000408	0.00277	CcSEcCtD
Fesoterodine—Nausea—Carmustine—melanoma	0.0004	0.00271	CcSEcCtD
Fesoterodine—Insomnia—Docetaxel—melanoma	0.000392	0.00266	CcSEcCtD
Fesoterodine—Nausea—Temozolomide—melanoma	0.000387	0.00262	CcSEcCtD
Fesoterodine—Somnolence—Docetaxel—melanoma	0.000385	0.00261	CcSEcCtD
Fesoterodine—Dyspepsia—Docetaxel—melanoma	0.000381	0.00259	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Docetaxel—melanoma	0.000374	0.00254	CcSEcCtD
Fesoterodine—Fatigue—Docetaxel—melanoma	0.000373	0.00253	CcSEcCtD
Fesoterodine—Constipation—Docetaxel—melanoma	0.00037	0.00251	CcSEcCtD
Fesoterodine—Feeling abnormal—Docetaxel—melanoma	0.000357	0.00242	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Docetaxel—melanoma	0.000354	0.0024	CcSEcCtD
Fesoterodine—Abdominal pain—Docetaxel—melanoma	0.000342	0.00232	CcSEcCtD
Fesoterodine—Hypersensitivity—Docetaxel—melanoma	0.000319	0.00216	CcSEcCtD
Fesoterodine—Asthenia—Docetaxel—melanoma	0.000311	0.00211	CcSEcCtD
Fesoterodine—Pruritus—Docetaxel—melanoma	0.000306	0.00208	CcSEcCtD
Fesoterodine—Diarrhoea—Docetaxel—melanoma	0.000296	0.00201	CcSEcCtD
Fesoterodine—Dizziness—Docetaxel—melanoma	0.000286	0.00194	CcSEcCtD
Fesoterodine—Rash—Docetaxel—melanoma	0.000273	0.00185	CcSEcCtD
Fesoterodine—Dermatitis—Docetaxel—melanoma	0.000273	0.00185	CcSEcCtD
Fesoterodine—Headache—Docetaxel—melanoma	0.000271	0.00184	CcSEcCtD
Fesoterodine—Nausea—Docetaxel—melanoma	0.000257	0.00174	CcSEcCtD
Fesoterodine—CHRM3—Signaling Pathways—KDR—melanoma	1.28e-05	0.000101	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KDR—melanoma	1.27e-05	9.98e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1B—melanoma	1.27e-05	9.93e-05	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—AKT1—melanoma	1.25e-05	9.82e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CD—melanoma	1.24e-05	9.76e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CXCL8—melanoma	1.24e-05	9.74e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CASP3—melanoma	1.24e-05	9.73e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—FN1—melanoma	1.24e-05	9.73e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL2—melanoma	1.24e-05	9.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—FN1—melanoma	1.24e-05	9.7e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—HRAS—melanoma	1.23e-05	9.67e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL6—melanoma	1.23e-05	9.67e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ALB—melanoma	1.23e-05	9.63e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—FN1—melanoma	1.22e-05	9.6e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NOTCH1—melanoma	1.21e-05	9.52e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1B—melanoma	1.21e-05	9.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NOTCH1—melanoma	1.21e-05	9.49e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCND1—melanoma	1.21e-05	9.47e-05	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—AKT1—melanoma	1.2e-05	9.4e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NOTCH1—melanoma	1.2e-05	9.4e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CTNNB1—melanoma	1.2e-05	9.38e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CD80—melanoma	1.19e-05	9.33e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CASP3—melanoma	1.19e-05	9.32e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CG—melanoma	1.19e-05	9.31e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KIT—melanoma	1.19e-05	9.31e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APC—melanoma	1.19e-05	9.31e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—NRAS—melanoma	1.19e-05	9.31e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—melanoma	1.19e-05	9.3e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CD80—melanoma	1.18e-05	9.3e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KIT—melanoma	1.18e-05	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—melanoma	1.18e-05	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APC—melanoma	1.18e-05	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—NRAS—melanoma	1.18e-05	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—melanoma	1.18e-05	9.26e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CD80—melanoma	1.17e-05	9.21e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ABCB1—melanoma	1.17e-05	9.21e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGF—melanoma	1.17e-05	9.2e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—melanoma	1.17e-05	9.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—melanoma	1.17e-05	9.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KIT—melanoma	1.17e-05	9.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APC—melanoma	1.17e-05	9.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—NRAS—melanoma	1.17e-05	9.19e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGF—melanoma	1.17e-05	9.17e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—melanoma	1.17e-05	9.16e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—melanoma	1.16e-05	9.14e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NFKB1—melanoma	1.16e-05	9.1e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGF—melanoma	1.16e-05	9.08e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—melanoma	1.16e-05	9.07e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PRKCA—melanoma	1.15e-05	8.99e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CTNNB1—melanoma	1.14e-05	8.98e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—melanoma	1.14e-05	8.92e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ERCC2—melanoma	1.14e-05	8.92e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK3—melanoma	1.14e-05	8.92e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK3—melanoma	1.13e-05	8.89e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—melanoma	1.12e-05	8.81e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK3—melanoma	1.12e-05	8.8e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—melanoma	1.12e-05	8.77e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—melanoma	1.12e-05	8.75e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—melanoma	1.12e-05	8.75e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—melanoma	1.11e-05	8.72e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NFKB1—melanoma	1.11e-05	8.71e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP17A1—melanoma	1.11e-05	8.68e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—melanoma	1.1e-05	8.64e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—melanoma	1.09e-05	8.54e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1—melanoma	1.09e-05	8.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—melanoma	1.08e-05	8.5e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1—melanoma	1.08e-05	8.5e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK1—melanoma	1.08e-05	8.48e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—melanoma	1.08e-05	8.48e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PRKCA—melanoma	1.08e-05	8.47e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK1—melanoma	1.08e-05	8.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—melanoma	1.08e-05	8.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—melanoma	1.07e-05	8.43e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1—melanoma	1.07e-05	8.41e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ERCC2—melanoma	1.07e-05	8.4e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK1—melanoma	1.07e-05	8.37e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—melanoma	1.07e-05	8.37e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—melanoma	1.05e-05	8.26e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAP2K1—melanoma	1.05e-05	8.24e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAP2K1—melanoma	1.05e-05	8.21e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GNA11—melanoma	1.04e-05	8.2e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—melanoma	1.04e-05	8.18e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—melanoma	1.04e-05	8.18e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—melanoma	1.04e-05	8.16e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NRAS—melanoma	1.04e-05	8.16e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAP2K1—melanoma	1.04e-05	8.13e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	1.03e-05	8.11e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	1.03e-05	8.08e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—melanoma	1.03e-05	8.08e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—FASN—melanoma	1.02e-05	8.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—melanoma	1.02e-05	8.01e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	1.02e-05	8e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—melanoma	1.02e-05	7.99e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—melanoma	1.01e-05	7.91e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—melanoma	1.01e-05	7.91e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC5A5—melanoma	1.01e-05	7.89e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—FGF2—melanoma	9.99e-06	7.84e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—melanoma	9.98e-06	7.83e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—FGF2—melanoma	9.95e-06	7.81e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK3—melanoma	9.95e-06	7.81e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NRAS—melanoma	9.95e-06	7.81e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—FGF2—melanoma	9.86e-06	7.73e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GNAQ—melanoma	9.71e-06	7.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CD44—melanoma	9.71e-06	7.62e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—melanoma	9.68e-06	7.6e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK3—melanoma	9.53e-06	7.48e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK1—melanoma	9.47e-06	7.43e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—melanoma	9.47e-06	7.43e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	9.38e-06	7.36e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—melanoma	9.36e-06	7.35e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—melanoma	9.35e-06	7.34e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—melanoma	9.34e-06	7.33e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1B1—melanoma	9.31e-06	7.31e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—melanoma	9.31e-06	7.31e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—melanoma	9.27e-06	7.27e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—melanoma	9.26e-06	7.27e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—melanoma	9.22e-06	7.24e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ERBB2—melanoma	9.21e-06	7.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ERBB2—melanoma	9.18e-06	7.21e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ERBB2—melanoma	9.09e-06	7.14e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—melanoma	9.09e-06	7.13e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK1—melanoma	9.07e-06	7.12e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—melanoma	9.07e-06	7.12e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—melanoma	9.06e-06	7.11e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—melanoma	8.97e-06	7.04e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—melanoma	8.97e-06	7.04e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—melanoma	8.94e-06	7.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—melanoma	8.74e-06	6.85e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—melanoma	8.71e-06	6.83e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—melanoma	8.68e-06	6.81e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARG—melanoma	8.66e-06	6.8e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—melanoma	8.65e-06	6.79e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—melanoma	8.62e-06	6.77e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—melanoma	8.57e-06	6.72e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—melanoma	8.57e-06	6.72e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1B—melanoma	8.53e-06	6.69e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1B—melanoma	8.5e-06	6.67e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—melanoma	8.46e-06	6.64e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—melanoma	8.44e-06	6.62e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1B—melanoma	8.42e-06	6.61e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—melanoma	8.41e-06	6.6e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—melanoma	8.36e-06	6.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—melanoma	8.35e-06	6.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—melanoma	8.33e-06	6.54e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—melanoma	8.33e-06	6.54e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—melanoma	8.32e-06	6.53e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—melanoma	8.31e-06	6.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—melanoma	8.28e-06	6.5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—melanoma	8.25e-06	6.48e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—melanoma	8.24e-06	6.47e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—melanoma	8.22e-06	6.45e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—melanoma	8.2e-06	6.43e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARG—melanoma	8.16e-06	6.4e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—melanoma	8.14e-06	6.39e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—melanoma	8.11e-06	6.37e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CTNNB1—melanoma	8.06e-06	6.32e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—melanoma	8.03e-06	6.3e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CTNNB1—melanoma	8.03e-06	6.3e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CTNNB1—melanoma	7.96e-06	6.24e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—melanoma	7.95e-06	6.24e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—melanoma	7.9e-06	6.2e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—melanoma	7.89e-06	6.19e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—melanoma	7.88e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—melanoma	7.87e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—melanoma	7.87e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—melanoma	7.85e-06	6.16e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—melanoma	7.85e-06	6.16e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—melanoma	7.83e-06	6.14e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NFKB1—melanoma	7.82e-06	6.13e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—melanoma	7.8e-06	6.12e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NFKB1—melanoma	7.79e-06	6.11e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—melanoma	7.79e-06	6.11e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—melanoma	7.77e-06	6.1e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—melanoma	7.75e-06	6.08e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NFKB1—melanoma	7.72e-06	6.06e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCB1—melanoma	7.67e-06	6.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—melanoma	7.66e-06	6.01e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—melanoma	7.64e-06	5.99e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—melanoma	7.61e-06	5.97e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—melanoma	7.6e-06	5.97e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—melanoma	7.56e-06	5.94e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—melanoma	7.43e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—melanoma	7.34e-06	5.76e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—melanoma	7.28e-06	5.71e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—melanoma	7.28e-06	5.71e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—melanoma	7.09e-06	5.57e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—melanoma	7.07e-06	5.55e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PRKCA—melanoma	7.06e-06	5.54e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—melanoma	7.02e-06	5.51e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NRAS—melanoma	7.01e-06	5.5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—melanoma	7e-06	5.5e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—melanoma	7e-06	5.49e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ERCC2—melanoma	7e-06	5.49e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NRAS—melanoma	6.99e-06	5.48e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—melanoma	6.97e-06	5.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—melanoma	6.93e-06	5.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NRAS—melanoma	6.92e-06	5.43e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—melanoma	6.88e-06	5.4e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—melanoma	6.81e-06	5.35e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—melanoma	6.71e-06	5.27e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK3—melanoma	6.71e-06	5.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK3—melanoma	6.69e-06	5.25e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK3—melanoma	6.62e-06	5.2e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—melanoma	6.61e-06	5.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—melanoma	6.53e-06	5.12e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—melanoma	6.51e-06	5.11e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—melanoma	6.48e-06	5.08e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—melanoma	6.44e-06	5.06e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—melanoma	6.43e-06	5.04e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—melanoma	6.42e-06	5.04e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK1—melanoma	6.39e-06	5.01e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—melanoma	6.38e-06	5.01e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK1—melanoma	6.37e-06	5e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—melanoma	6.36e-06	4.99e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK1—melanoma	6.3e-06	4.95e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—melanoma	6.3e-06	4.95e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—melanoma	6.03e-06	4.73e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—melanoma	6.01e-06	4.72e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—melanoma	5.95e-06	4.67e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—melanoma	5.94e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—melanoma	5.6e-06	4.39e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—melanoma	5.54e-06	4.35e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—melanoma	5.53e-06	4.34e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—melanoma	5.52e-06	4.33e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—melanoma	5.47e-06	4.29e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—melanoma	5.4e-06	4.23e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—melanoma	5.36e-06	4.21e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—melanoma	5.34e-06	4.19e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARG—melanoma	5.34e-06	4.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—melanoma	5.29e-06	4.15e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—melanoma	5.13e-06	4.02e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—melanoma	5.11e-06	4.01e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—melanoma	5.06e-06	3.97e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—melanoma	4.91e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—melanoma	4.89e-06	3.84e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—melanoma	4.86e-06	3.81e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—melanoma	4.84e-06	3.8e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—melanoma	4.8e-06	3.76e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—melanoma	4.53e-06	3.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—melanoma	4.51e-06	3.54e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—melanoma	4.47e-06	3.51e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—melanoma	4.24e-06	3.32e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—melanoma	4.2e-06	3.29e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—melanoma	4.19e-06	3.29e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—melanoma	3.95e-06	3.1e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—melanoma	3.66e-06	2.87e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—melanoma	3.42e-06	2.69e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—melanoma	3.23e-06	2.53e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—melanoma	2.58e-06	2.03e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—melanoma	2.11e-06	1.66e-05	CbGpPWpGaD
